HYFT Stock Analysis: Buy, Sell, or Hold?
HYFT - MindWalk Holdings Corp. Common Stock
$1.41
0.04 (2.92%)
â˛
5d:
+0.0%
30d:
+19.49%
90d:
-8.44%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Sep 21, 2026
28d
Get Alerted When HYFT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HYFT is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HYFT is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: HYFT is currently trading at $1.41, which is considered slightly high relative to its 30-day fair value range of $1.30 to $1.44. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.6) compared to its historical average (85.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HYFT is in a uptrend. Immediate support is located at $1.25, while resistance sits at $1.50.
Market Sentiment: HYFT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.33 (+207.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HYFT is in a uptrend. Immediate support is located at $1.25, while resistance sits at $1.50.
Market Sentiment: HYFT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.33 (+207.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.30 -
$1.44
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 207.3% below Wall St target ($4.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.30 -
$1.44
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.25
Resistance Level
$1.50
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.56
Wall Street Target
$4.33
(+207.3%)
Revenue Growth (YoY)
49.8%
Profit Margin
-89.7%
PE vs Historical
-7.6 vs 85.2
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 12:41 PM ET
Data refreshes hourly during market hours. Next update: 1:41 PM
Data refreshes hourly during market hours. Next update: 1:41 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HYFT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |